89bio to Participate in the Cantor Global Healthcare Conference

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced a corporate update and one-on-one investor meetings at the Cantor Global Healthcare Conference on September 28, 2021, at 2:40 p.m. ET. The event will be virtual, and the presentation can be accessed via the investor section of 89bio's website. The company focuses on innovative therapies for liver and cardio-metabolic diseases, with its lead candidate BIO89-100 targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

SAN FRANCISCO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Cantor Global Healthcare Conference, a virtul event, on Tuesday, September 28, 2021 at 2:40 p.m. ET.

The webcast of the presentation will be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

 

FAQ

What event will 89bio, Inc. participate in on September 28, 2021?

89bio, Inc. will participate in the Cantor Global Healthcare Conference on September 28, 2021.

At what time will 89bio's presentation begin during the Cantor Global Healthcare Conference?

89bio's presentation will begin at 2:40 p.m. ET.

How can investors access the webcast of 89bio's presentation?

Investors can access the webcast via the investor section of 89bio's website.

What is the focus of 89bio, Inc. in the biopharmaceutical industry?

89bio, Inc. focuses on developing therapies for liver and cardio-metabolic diseases.

What is 89bio's lead product candidate?

89bio's lead product candidate is BIO89-100, which targets NASH and severe hypertriglyceridemia.